Trial Profile
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Trametinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 21 Dec 2020 Status changed from active, no longer recruiting to completed.
- 10 Jun 2020 Planned number of patients changed from 30 to 24.
- 10 Jun 2020 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.